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OBJECTIVES This study sought to determine the independent association of renal insufficiency with
cardiovascular risk among women with known coronary heart disease (CHD).
BACKGROUND Although patients with end-stage renal disease and proteinuria are at high risk for
cardiovascular events, little is known about the cardiovascular risk associated with moderate
renal insufficiency.
METHODS The Heart and Estrogen/progestin Replacement Study (HERS) was a clinical trial among
2,763 women with coronary disease who were randomized to conjugated estrogen plus
progestins or identical placebo and followed for a mean of 4.1 years. Women were categorized
as having normal renal function (creatinine , 1.2 mg/dl; n 5 2,012), mild renal insufficiency
(1.2 mg/dl to 1.4 mg/dl; n 5 567) and moderate renal insufficiency (.1.4 mg/dl; n 5 182).
We examined the independent association of renal function with incident cardiovascular
events including CHD death, nonfatal myocardial infarction, hospitalization for unstable
angina, stroke and transient ischemic attacks.
RESULTS Compared with women with normal renal function, those with mild and moderate renal
insufficiency were older, more likely to be black, have a history of hypertension and diabetes
and have higher serum levels of triglycerides and lipoprotein(a). After multivariate adjust-
ment, both mild (relative hazards [RH] 5 1.24; 95% confidence interval [CI]: 1.0 to 1.5) and
moderate renal insufficiency (RH 5 1.57; 95% CI: 1.2 to 2.1) were independently associated
with increased risk for cardiovascular events compared with women with normal renal
function.
CONCLUSIONS Renal insufficiency is an independent risk factor for cardiovascular events in postmenopausal
women with known coronary artery disease. Renal function may add helpful information to
CHD risk stratification. (J Am Coll Cardiol 2001;38:705–11) © 2001 by the American
College of Cardiology
Patients with end-stage renal disease have a markedly
elevated risk of coronary heart disease (CHD) and other
vascular disease events (1,2), perhaps as a result of lipopro-
tein abnormalities, elevated serum homocysteine levels and
an increased risk of thrombosis (3–5). Several of these
abnormalities, such as elevated lipoprotein(a) and homocys-
teine, are also present in patients with moderate renal
insufficiency. The most common causes of renal insuffi-
ciency, hypertension and diabetes mellitus are also indepen-
dent risk factors for CHD events. Although there is
considerable evidence that end-stage renal disease indepen-
dently increases the risk of CHD, less is known about the
relation between mild-to-moderate renal insufficiency and
CHD (6).
Studies in subjects without CHD have found that renal
insufficiency is associated with all-cause mortality, and some
studies have found an independent association of renal
insufficiency with cardiovascular events (7–11). One study
found renal insufficiency to increase the risk of CHD events
in a sample that included persons with and without preva-
lent vascular disease (12). To test the hypothesis that
mild-to-moderate renal insufficiency increases the risk for
CHD events, we analyzed data collected in the Heart and
Estrogen/progestin Replacement Study (HERS), a clinical
trial of the effect of hormone therapy among 2,763 post-
menopausal women.
METHODS
Subjects. The design, methods and primary results of
HERS have been published (13,14). Briefly, HERS partic-
ipants were postmenopausal women aged ,80 years with
established CHD who had not had a hysterectomy. Inclu-
sion criteria were prior myocardial infarction (MI), coronary
artery bypass graft surgery (CABG), percutaneous coronary
revascularization (PTCA) or angiographic evidence of a
50% occlusion of one or more major coronary arteries.
Exclusion criteria were a recent CHD event, New York
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Heart Association class IV or severe class III congestive
heart failure, serum triglyceride level .300 mg/dl, recent
use of any hormone therapy, uncontrolled hypertension or
diabetes, a disease (other than CHD) judged likely to be
fatal within four years or intolerance to hormone replace-
ment therapy. Participants were randomly assigned to re-
ceive a single identical tablet containing either conjugated
equine estrogen 0.625 mg and medroxyprogesterone acetate
2.5 mg or placebo.
Measurements. Demographic characteristics, health his-
tory, CHD risk factors, medication use, educational level
and quality of life were assessed at baseline. Baseline levels
of fasting total cholesterol, low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, triglycerides and
lipoprotein(a) were determined by the Lipoprotein Analyt-
ical Laboratory at Johns Hopkins Hospital. Serum creati-
nine levels were measured at the initial examination visit in
all but one participant. We excluded one additional partic-
ipant with an initial serum creatinine level of 9.3 mg/dl. The
serum creatinine level was measured on unfrozen serum at
SmithKline Beecham Clinical Labs. In addition, we esti-
mated the creatinine clearance for each participant using the
Cockcroft-Gault equation [(140 2 age) z body mass/
72 z creatinine] z 0.85 (in women) (15).
Follow-up and outcome assessment. Follow-up visits to
the clinical centers occurred every four months over a mean
of 4.1 years. All suspected outcome events were classified
independently by two physician reviewers unaware of treat-
ment assignment, and discordant classifications were re-
solved in discussions between the reviewers.
The primary outcome of this study was a composite
cardiovascular disease outcome that included CHD death,
nonfatal MI, unstable angina and cerebrovascular disease
events. Coronary heart disease death was defined as fatal
MI, sudden death within 1 h of symptoms, unobserved
death that occurred out of the hospital in the absence of
other known causes or death due to a coronary revascular-
ization procedure or congestive heart failure. Diagnosis of
MI was based on an algorithm that incorporated clinical
symptoms, electrocardiogram (ECG) abnormalities and
cardiac enzyme levels (13). The diagnosis of unstable angina
required a hospital admission for suspected coronary isch-
emia and the presence of ST-segment or T-wave changes
on the ECG. Cerebrovascular disease included both stroke
and transient ischemic attacks (TIA). We did not include
PTCA and CABG as outcomes in these analyses because of
concern that participants with elevated serum creatinine
levels might be less likely to be referred for these procedures.
We also analyzed the data using a composite cardiovascular
outcome that included revascularization events, and the
results were virtually identical.
Statistical analysis. To evaluate the association of baseline
serum creatinine levels and incident cardiovascular events,
we began by calculating unadjusted cardiovascular event
rates for each 0.1 mg/dl and 0.5 mg/dl increment in serum
creatinine. We then used multivariate proportional hazards
models, including all the variables listed in Table 1, to
determine the independent association of serum creatinine
and cardiovascular events. Using stepwise regression proce-
dures, we retained in the model only those variables that
were associated with the outcome at a significance level of p
,0.2. We tested the assumption of log-linearity of serum
creatinine level with cardiovascular events by including
linear and quadratic terms for serum creatinine and found
that the association was unchanged.
The serum creatinine level was also analyzed as an ordinal
categorical variable. We defined moderate renal insuffi-
ciency as a serum creatinine level .1.4 mg/dl, the 95th
percentile among women in the Framingham Heart study
(16). Based on the National Kidney Foundation definition
of normal creatinine levels in women (1.2 mg/dl), we
divided the remaining participants into two groups: mild
renal insufficiency (1.2 to 1.4 mg/dl) and normal renal
function (,1.2 mg/dl) (17). The time to first new cardio-
vascular event was initially compared among the three
groups using Kaplan-Meier survival curves, and the log-
rank test was used to test for differences in the survival
curves. We then evaluated the multivariate-adjusted relative
hazards (RH) associated with mild and moderate renal
insufficiency compared with women with normal renal
function using the methods described above. For compari-
son, we contrasted the risk of cardiovascular events associ-
ated with diabetes mellitus with the risk associated with
moderate renal insufficiency.
In addition, we determined the association of estimated
creatinine clearance (categorized as .60 ml/min, 40 to 60
ml/min and ,40 ml/min) with cardiovascular events. Using
proportional hazards models, we determined the risk of
cardiovascular disease events for women in each category of
reduced creatinine clearance.
We hypothesized that four variables might interact with
renal function in predicting CHD events: prior history of
diabetes or hypertension, use of angiotensin-converting
enzyme (ACE) inhibitors and hormone therapy. We tested
for interactions with these variables and calculated adjusted
RH for patients with moderate renal insufficiency after
stratifying for these characteristics.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CABG 5 coronary artery bypass graft surgery
CHD 5 coronary heart disease
CI 5 confidence interval
ECG 5 electrocardiogram
HERS 5 Heart and Estrogen/progestin Replacement
Study
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
RH 5 relative hazards
TIA 5 transient ischemic attack
706 Shlipak et al. JACC Vol. 38, No. 3, 2001
Renal Disease and Cardiovascular Events September 2001:705–11
All analyses were conducted using SAS 6.12 software. A
two-tailed p value ,0.05 was considered statistically signif-
icant.
RESULTS
Baseline characteristics. Among the 2,761 participants
included in this analysis, 2,012 (73%) had normal renal
function (creatinine level , 1.2 mg/dl); 567 (21%) had mild
renal insufficiency (creatinine level 1.2 mg/dl to 1.4 mg/dl),
and 182 (7%) had moderate renal insufficiency (creatinine
level . 1.4 mg/dl) at baseline (Fig. 1).
Compared with women with normal renal function,
women with mild and moderate renal insufficiency were
older and more often black and had a higher prevalence of
hypertension, diabetes mellitus and prior CABG (Table 1).
Participants with renal insufficiency were also less likely to
use alcohol and were more likely to rate their activity level as
“less active than peers” than women with normal renal
function. Baseline serum triglyceride and lipoprotein(a)
levels were highest among women with moderate renal
insufficiency. Among the three groups of women, aspirin
use was lowest in women with renal insufficiency and use of
ACE inhibitors was highest.
Association between serum creatinine level and cardio-
vascular events. In unadjusted analysis, cardiovascular
event rates increased with increasing creatinine levels (p ,
0.001) (Fig. 2). After multivariate adjustment, each 0.5 mg/dl
increase in serum creatinine was independently associated
with 23% increased risk (95% confidence interval [CI]: 10 to
38%) for all cardiovascular events, a 36% increased risk (95%
CI: 11 to 65%) for CHD death and an 18% increased risk
(95% CI: 8 to 30%) for stroke and TIA. Higher serum
creatinine levels were marginally associated with increased
risk for nonfatal MI (20%; 95% CI: 21 to 46%) and
unstable angina (15%; 95% CI: 27 to 42%).
Association of mild and moderate renal insufficiency with
cardiovascular events. Mild (1.2 to 1.4 mg/dl) and mod-
erate (.1.4 mg/dl) renal insufficiency were associated with
increased risk for cardiovascular events (Fig. 3). After
multivariate adjustment, mild and moderate renal insuffi-
ciency remained independent predictors of cardiovascular
events (Table 2). The independent association of moderate
Table 1. Characteristics of Participants by Creatinine Level at Baseline
Characteristics
<1.2 mg/dl
(n 5 2,012)
1.2–1.4 mg/dl
(n 5 567)
>1.4 mg/dl
(n 5 182)
p
Value*
Mean 6 SD or Percent
Age (yrs) 66 6 7 68 6 6 68 6 7 ,0.001
Race (%)
White 91 87 76 ,0.001
Black 6 11 21
Other 4 2 3
Diabetes (%) 20 26 44 ,0.001
Hypertension (%) 55 66 77 ,0.001
Prior myocardial infarction (%) 51 53 59 0.14
Prior PTCA (%) 45 43 38 0.22
Prior CABG (%) 40 42 51 0.01
Current tobacco use (%) 14 12 12 0.46
LDL-cholesterol (mg/dl) 145 6 38 145 6 36 147 6 43 0.72
HDL-cholesterol (mg/dl) 51 6 13 49 6 13 49 6 14 0.12
Triglyceride level (mg/dl) 160 6 61 168 6 64 182 6 67 0.002
Lipoprotein(a) (mg/dl) 33 6 32 35 6 33 38 6 36 0.05
Body mass index (kg/m2) 28 6 6 29 6 6 29 6 5 0.01
Education (yrs) 13 6 3 13 6 3 12 6 3 0.02
Alcohol consumption (%)
None 58 68 72 ,0.001
,5 drinks/week 19 15 14
$5 drinks/week 23 17 14
Activity less than peers (%) 23 28 47 ,0.001
Aspirin use (%) 80 76 72 0.004
Lipid-lowering agent use (%) 36 37 42 0.17
Beta-blocker use (%) 32 34 32 0.70
ACE inhibitor use (%) 15 24 30 ,0.001
Calcium channel blockers (%) 54 56 60 0.27
Randomization to postmenopausal
hormone therapy (%)
50 50 54 0.55
*p values based on chi-square tests for proportions and analysis of variance for continuous values.
ACE 5 angiotensin-converting enzyme; CABG 5 coronary artery bypass grafting; HDL 5 high-density lipoprotein;
LDL 5 low-density lipoprotein; PTCA 5 percutaneous transluminal coronary angioplasty.
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renal insufficiency with CHD death and stroke/TIA
reached statistical significance, but the association with
nonfatal MI or unstable angina did not. For comparison,
diabetes was associated with a 47% increased risk (95% CI:
20 to 80%) for cardiovascular events, whereas moderate
renal insufficiency was associated with a 57% (95% CI: 20 to
110%) increased risk.
Estimated creatinine clearance and cardiovascular
events. A total of 322 (12%) women had an estimated
creatinine clearance of ,40 ml/min, and 1,135 (41%)
Figure 1. Distribution of serum creatinine levels (mg/dl) among 2,761 Heart and Estrogen/progestin Replacement study participants.
Figure 2. Cardiovascular event rates by serum creatinine level at entry into the Heart and Estrogen/progestin Replacement study. The percentage of women
experiencing an event is displayed with 95% confidence intervals. Cardiovascular events include coronary heart disease death, nonfatal myocardial infarction,
hospitalization for unstable angina, stroke and transient ischemic attacks.
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participants had an estimated creatinine clearance between
40 to 60 ml/min. Creatinine clearance ,40 ml/min was
associated with increased risks for all cardiovascular events,
nonfatal MI, CHD death and stroke and TIA that were
similar in magnitude to the risks associated with a serum
creatinine level .1.4 mg/dl (Table 3). Creatinine clearance
of 40 to 60 ml/min was associated with a modest elevation
in risk for all cardiovascular events compared with women
who had a creatinine clearance .60 ml/min.
Potential interactions. The increased risk for cardiovascu-
lar events associated with moderate renal insufficiency (se-
rum creatinine level .1.4 mg/dl) was similar among women
with hypertension (RH 5 1.57; 95% CI: 1.2 to 2.1) and
without hypertension (1.63; 95% CI: 0.9 to 3.0), with
diabetes (RH 5 1.74; 95% CI: 1.1 to 2.7) and without
diabetes (RH 5 1.48; 1.0 to 2.1), women using ACE
inhibitors (RH 5 1.46; 0.9 to 2.5) and women not using
ACE inhibitors (RH 5 1.62; 1.2 to 2.2) and among women
randomly assigned to hormone therapy (RH 5 1.47; 1.0 to
2.2) and those assigned to placebo (RH 5 1.73; 1.2 to 2.5).
DISCUSSION
New findings. The prevalence of chronic renal insuffi-
ciency, defined as a serum creatinine level .1.4 mg/dl, was
estimated to be 10.9 million persons in the U.S. in the
Third National Health and Nutrition Examination Survey
(NHANES III) (18). Despite the high prevalence, chronic
renal insufficiency has not been well characterized (6). We
found that mild and moderate renal insufficiency were
independent predictors of cardiovascular events in post-
menopausal women with CHD.
Characterized either as a serum creatinine level .1.4 mg/dl
or an estimated creatinine clearance of ,40 ml/min, mod-
erate renal insufficiency was associated with 60% to 80%
increased risk of cardiovascular events. For comparison,
diabetes was associated with a 50% increased risk for
cardiovascular events among HERS participants. The asso-
ciation of renal insufficiency with cardiovascular outcomes
persisted among subgroups with and without hypertension
and diabetes and treatment with ACE inhibitors or hor-
mone therapy. Even mild renal insufficiency, defined by
Figure 3. Kaplan-Meier curve demonstrating cardiovascular event-free
survival among women in the Heart and Estrogen/progestin Replacement
study based on the presence of renal insufficiency. Increasing levels of renal
insufficiency were associated with greater cardiovascular event rates.
Table 2. Association of Serum Creatinine Level With Cardiovascular Events
<1.2 mg/dl
(n 5 2,012)
1.2–1.4 mg/dl
(n 5 567)
>1.4 mg/dl
(n 5 182)
All cardiovascular events
Number 442 168 72
Incidence (per 1,000 person-years) 60 88 131
Multivariate-adjusted RH (95% CI) 1.0 1.24 (1.0–1.5) 1.57 (1.2–2.1)
Nonfatal myocardial infarction
Number 169 62 25
Incidence (per 1,000 person-years) 21 29 40
Multivariate-adjusted RH (95% CI) 1.0 1.24 (0.9–1.7) 1.46 (0.9–2.3)
CHD death
Number 69 37 22
Incidence (per 1,000 person-years) 8 17 33
Multivariate-adjusted RH (95% CI) 1.0 1.43 (0.9–2.2) 1.99 (1.2–3.4)
Unstable angina
Number 153 57 19
Incidence (per 1,000 person-years) 19 28 30
Multivariate-adjusted RH (95% CI) 1.0 1.23 (0.9–1.7) 1.21 (0.7–2.0)
Stroke and TIA
Number 126 57 31
Incidence (per 1,000 person-years) 16 27 51
Multivariate-adjusted RH (95% CI) 1.0 1.29 (0.9–1.7) 2.06 (1.4–3.1)
Variables retained in the multivariate models include age, race, hypertension, diabetes, tobacco use, prior coronary artery bypass
surgery, body mass index, waist-to-hip ratio, high-density lipoprotein level, triglyceride level, lipoprotein(a) level, alcohol use,
physical activity, education level, aspirin use, angiotensin-converting enzyme inhibitor use and diuretic use. The stroke/TIA
model is also adjusted for the presence of baseline atrial fibrillation.
CHD 5 coronary heart disease; CI 5 confidence interval; RH 5 relative hazards; TIA 5 transient ischemic attack.
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serum creatinine 1.2 to 1.4 mg/dl or an estimated creatinine
clearance of 40 to 60 ml/min, was associated with a 20% to
30% increased risk for cardiovascular events.
Our study provides evidence that the cardiovascular risk
associated with decrements in renal function may increase
steadily from near-normal renal function to end-stage renal
disease. Prior studies have demonstrated that end-stage
renal disease is associated with a substantial increase in the
risk for cardiovascular events (19,20). Microalbuminuria, a
marker for early renal damage, is also associated with
increased cardiovascular risk (21,22). Our findings lend
support to the hypothesis that the increased cardiovascular
risk associated with renal disease increases on a continuum
from preclinical renal injury to end-stage renal disease, as
suggested by the National Kidney Foundation Task Force
on cardiovascular disease (6,17,23).
Potential mechanisms. The mechanism by which renal
insufficiency might increase the risk for cardiovascular
events is not clear. Renal insufficiency is associated with a
greater prevalence of cardiovascular risk factors, such as
diabetes, hypertension and lipid abnormalities, but we
adjusted for these in our multivariate analyses. We were
unable to adjust for other potential risk factors associated
with renal dysfunction, such as higher homocysteine levels
and increased systemic inflammation (24–28). Direct effects
of renal disease that could lead to greater cardiovascular
disease risk also include extracellular volume overload,
electrolyte imbalances, anemia, thrombogenic factors, oxi-
dative stress and uremic toxins (6). These mechanisms may
be intermediaries on a causal pathway leading from renal
dysfunction to cardiovascular events. Alternatively, chronic
renal insufficiency could merely be a marker for target organ
damage that parallels the progression of vascular disease.
Prior studies. Several prior studies have demonstrated an
association between renal insufficiency and all-cause mor-
tality and stroke (7–9,29–31). The Framingham Heart
study, however, did not find chronic renal insufficiency to be
an independent predictor of cardiovascular risk (9). Al-
though renal insufficiency was associated with cardiovascu-
lar events in unadjusted analyses, the association was mark-
edly attenuated after multivariate adjustment. The major
difference between HERS and the Framingham study was
the composition of the population. The Framingham cohort
included a minority of subjects with known cardiovascular
disease (,20%), whereas HERS included only postmeno-
pausal women with CHD. In the Heart Outcomes Preven-
tion Evaluation (HOPE) study, which was comprised of
persons both with and without prevalent cardiovascular
disease, renal insufficiency was a strong predictor of both MI
and cardiovascular death (12).
Study limitations. One limitation of this study is the
reliance on the serum creatinine level and estimated creat-
inine clearance, which are less precise measures of renal
function than creatinine clearance measured with 24-h urine
collection. Furthermore, we relied on a single measurement
of serum creatinine, which may be less reliable than the
mean of a series of measurements. This potential misclas-
sification, however, would tend to weaken the association
between renal function and cardiovascular events. In addi-
tion, our participants were postmenopausal women with
documented coronary artery disease; our findings may not
be generalizable to men or to those without CHD.
Table 3. Association of Estimated Creatinine Clearance With Cardiovascular Events
>60 ml/min
(n 5 1,306)
40–60 ml/min
(n 5 1,135)
<40 ml/min
(n 5 322)
All cardiovascular events
Number 275 287 119
Incidence (per 1,000 person-years) 56 72 118
Multivariate-adjusted RH (95% CI) 1.0 1.28 (1.0–1.6) 1.76 (1.3–2.3)
Myocardial infarction
Number 112 105 39
Incidence (per 1,000 person-years) 22 24 35
Multivariate-adjusted RH (95% CI) 1.0 1.24 (0.9–1.6) 1.65 (1.1–2.4)
CHD death
Number 49 48 30
Incidence (per 1,000 person-years) 9 10 25
Multivariate-adjusted RH (95% CI) 1.0 1.33 (0.9–2.1) 2.56 (1.5–4.3)
Unstable angina
Number 89 109 31
Incidence (per 1,000 person-years) 17 25 28
Multivariate-adjusted RH (95% CI) 1.0 1.40 (1.0–1.9) 1.37 (0.9–2.2)
Stroke and TIA
Number 70 93 51
Incidence (per 1,000 person-years) 13 21 46
Multivariate-adjusted RH (95% CI) 1.0 1.31 (0.9–1.9) 2.03 (1.3–3.3)
Variables retained in the multivariate models include age, race, hypertension, diabetes, tobacco use, prior coronary artery bypass
surgery, body mass index, waist-to-hip ratio, low-density lipoprotein cholesterol level, high-density lipoprotein cholesterol level,
triglyceride level, lipoprotein(a) level, physical activity, lipid lowering medication use and diuretic use. The stroke/TIA model is
also adjusted for the presence of baseline atrial fibrillation.
CHD 5 coronary heart disease; CI 5 confidence interval; RH 5 relative hazards; TIA 5 transient ischemic attack.
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Conclusions. In conclusion, renal insufficiency was a
strong and independent predictor of cardiovascular events in
postmenopausal women with known coronary artery dis-
ease. This study supports the hypothesis that declining renal
function, from mild reductions to end-stage renal disease,
may steadily increase the risk for cardiovascular events.
Future investigations should evaluate the mechanisms for
this association and devise strategies to improve prevention
in these patients at increased cardiovascular risk.
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